Novartis Investigative site

Newport News, Virginia 23608

0 studies enrolling now · 18 studies all time

What they study most

Acute Gouty Arthritis, Acute Gouty Arthritis Flares, Asthma, Cancer, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Hepatitis C, Liver Disease, Multiple Sclerosis, Non-alcoholic Steatohepatitis NASH, Obesity, Overweight

Studies at this site

• Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma — Completed
• Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients — Completed
• β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3) — Completed
• Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH — Stopped early
• A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults — Completed
• Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone — Stopped early
• Efficacy and Safety Study of QVA149 in COPD Patients — Completed
• Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option — Completed
• Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants — Completed
• Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C — Stopped early
• A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation — Completed
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients — Completed
• Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• 12-week Efficacy of Indacaterol — Completed